Back To Schedule
Wednesday, June 28 • 10:30am - 11:30am
Patient-Focused Drug Development in Rare Disease Endpoint Selections

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session
Level: Intermediate

There are many challenges facing the new drug development for rare diseases. Overcoming these challenges and therefore to achieve optimal drug development for rare disease require implementations of innovative design and analysis methods as well as strategic collaborations among regulatory, sponsors, physicians, institutions, and patients and patient groups. For this session, we will focus on one critical need in rare disease new drug development-endpoint selections.


Susan Wang, PhD

avatar for Susan Wang

Susan Wang

Global Head of Biostatistics and Data Sciences Inflammation, Boehringer Ingelheim, United States
Dr. Susan Wang is the global head of biostatistics and Datas Sciences in inflammatory diseases at Boehringer-Ingelheim Pharmaceuticals, Inc., in Ridgefield, Connecticut. She has many years of experiences working on global drug developments and registrations as a lead statistician... Read More →

Wednesday June 28, 2023 10:30am - 11:30am CDT
TBD Boston Convention and Exhibition Center 415 Summer Street, Boston, MA 02210 USA
  11: Statistics, Session